7-aminocephalosporanic acid derivative as inhibitor of il-15 and il-2 activity

Abstract

The invention relates to 7-zminocephalosporanic acid derivative, Cefazolin, for use as the inhibitor of IL-15 and IL-2 receptors in the prevention and treatment of IL-15 and IL-2 overproduction related diseases.

1 . 7-Aminocephalosporanic acid derivative—Cefazolin, for use as the inhibitor of IL-15 and IL-2 receptors in the prevention and treatment of IL-15 and IL-2 overproduction related diseases. 
     
     
         2 . Cefazolin for use according to  claim 1 , wherein the disease is rheumatoid arthritis, psoriasis, inflammatory bowel disease, sarcoidosis, T-cell leukemias or transplant rejection. 
     
     
         3 . Cefazolin for use according to  claim 1 , wherein the disease is rheumatoid arthritis. 
     
     
         4 . Cefazolin for use according to  claim 1 , wherein Cefazolin is to be administered in a therapeutically effective dose to an individual in need of such a treatment. 
     
     
         5 . Cefazolin for use according to  claim 4 , wherein Cefazolin is to be administered as a single dosage form. 
     
     
         6 . Use of Cefazolin for manufacturing of the pharmaceutical formulation for the prevention and treatment of the diseases such as rheumatoid arthritis, psoriasis, inflammatory bowel disease, sarcoidosis, T-cell leukemias or transplant rejection. 
     
     
         7 . Pharmaceutical formulation comprising therapeutically effective amount of Cefazolin as the active ingredient and pharmaceutically acceptable carriers and/or excipients for use in the prevention and treatment of the diseases such as rheumatoid arthritis, psoriasis, inflammatory bowel disease, sarcoidosis, T-cell leukemias or transplant rejection. 
     
     
         8 . Pharmaceutical formulation according to  claim 7 , in a form suitable for intra-venous or intra-muscular administration.